Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2010-01-07 Regulatory Filings
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2010
Regulatory Filings
2010-01-07 English
Regulatory Filings 2010
Regulatory Filings
2010-01-07 English
Regulatory Filings 2010
Regulatory Filings Classification · 95% confidence The document is a letter from pSivida Corp. to the SEC requesting acceleration of the effective date for registration statements on Form S-3. It is a correspondence related to regulatory filings and does not contain financial data, report content, or detailed disclosures. The document is short (1927 characters) and serves as a procedural communication rather than a report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and correspondence with the SEC.
2010-01-05 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel to the SEC regarding the withdrawal of prior requests for acceleration of the effective date of two Registration Statements on Form S-3. It references registration statements related to the company's registration of shares and securities. The document is short (1490 characters) and is correspondence related to regulatory filings, not the filings themselves. It does not contain financial data or report content but is a regulatory communication about filings. Therefore, it fits best under Regulatory Filings (RNS).
2009-12-28 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a correspondence letter dated December 23, 2009, from the legal counsel of pSivida Corp. to the SEC Division of Corporation Finance. It responds to a comment letter regarding the company's Registration Statement on Form S-3 filed on November 25, 2009. The letter discusses eligibility to use Form S-3 for a securities offering, provides calculations related to share ownership and market value, and requests acceleration of the effective date of the Registration Statement. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory correspondence related to a registration filing, not a financial report or announcement of voting results. It fits best under Regulatory Filings (RNS) as it is a formal response to SEC comments on a registration statement.
2009-12-23 English
Regulatory Filings 2009
Regulatory Filings Classification · 100% confidence The document is a correspondence letter from the company's legal counsel to the SEC Division of Corporation Finance, responding to comments on a Registration Statement on Form S-3 filed by the company. It discusses eligibility to use Form S-3 for a securities offering, details about share ownership, and requests acceleration of the effective date of the Registration Statement. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory correspondence related to a securities registration filing, not a financial report or earnings release. It fits best under Regulatory Filings (RNS) as it is a formal response to SEC comments and does not constitute a report or announcement of financial results or corporate actions like capital changes or management changes.
2009-12-23 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.